Metsera, a clinical-stage biotech startup, has launched with a significant funding round of $290 million, aimed at developing obesity drugs. The funding was led by ARCH Venture Partners and included contributions from SoftBank and Mubadala Capital. Metsera plans to challenge major pharmaceutical companies like Lilly and Novo in the obesity treatment market. The company, backed by investors including Population Health Partners, has one of the most extensive pipelines for obesity drug development, having evaluated 200 companies' assets. Metsera CEO Clive Meanwell is leading the company's clinical strategy.
Metsera, a well-funded obesity drug #startup, sees chance to challenge Lilly, Novo https://t.co/v7FhEasBO7 by @BentheFidler $LLy $NVO
Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. https://t.co/oXqQPiGXE6
Weight-loss drug developer Metsera raises $290 million in funding https://t.co/8xHEKHRdD4 https://t.co/fIpsw2BOKP
Metsera comes out of stealth with $290 million for #obesity drugs Where there’s profit, there’s investment @statnews @elaineywchen https://t.co/kZmeDaTjFM
📰OBESITY: New News today, but you heard about it here a month ago (via great work by EndPts) Weight-loss drug developer Metsera raises $290 million in funding https://t.co/pOQys00wa6 https://t.co/WVZYi6G8lX
After scouring 200 companies’ pipelines, a new biotech firm is launching with one of the most wide-ranging pipelines yet for obesity drug development. https://t.co/BLKzUiJUyu
Metsera comes out of stealth with $290 million for obesity drugs https://t.co/Om4xTWzylE
“You don’t want to waste investors’ money on something you dream is better, but it turns out to be actually not as good,” Meanwell said. Here's how Metsera CEO Clive Meanwell thinks about clinical strategy in taking on Lilly, Novo in obesity: https://t.co/TzuODtCkXK
Congratulations to the entire Metsera team on your launch. This launch will help to accelerate innovation and the future sustainable weight management treatments for #obesity-related conditions. Learn more: https://t.co/BBiHf9N2Vy #healthcare #biopharma @FierceBiotech
Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture Partners as well as participation from firms such as SoftBank and Mubadala Capital, the company said on Thursday. https://t.co/DoIPek726I https://t.co/DoIPek726I
Thank you Kristina Burow for getting a new photo with a smile. It's great. Your old photo scared the hell out of me. Clive Meanwell is pulling the -- rather thin -- veil off of Metsera and their plans to buy up obesity assets to get after it. They're both ideally suited to that…
A new biotech backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development. https://t.co/nvcEYt7jhw
ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs https://t.co/iVRkBdGBTM via @ADeAngelis_bio
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo https://t.co/npROpQ8ohF $LLY $NVO #biotech #startups